Niraparib
Small molecule
Also known as GSK3985771
Evidence outlook
Approved: Ovarian Cancer
Regulatory approval supersedes design-level evidence grading; the trials behind approval are preserved below as the drug's evidence history.
track record: Reliable signal
Also in development:Non-Small Cell Lung Cancer · Phase 3Glioblastoma · Phase 3
Also approved (4)
- Maintenance Treatment of Recurrent Germline BRCA -Mutated Ovarian Cancer ZEJULA is indicated for the maintenance treatment of adult patients with deleterious or suspected deleterious germline BRCA -mutated (g BRCA mut) recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer who are in a complete or partial response to platinum-based chemotherapy. Select patients for therapy based on an FDA‑authorized companion diagnostic for ZEJULA [see Dosage and Administration ( 2.1 )] .
- Maintenance therapy, recurrent ovarian cancer (brand Zejula, Zai Lab)
- ZEJULA (niraparib capsules and tablets) is indicated: • as monotherapy for the maintenance treatment of female adult patients with advanced epithelial ovarian, fallopian tube, or primary peritoneal cancer who are in a complete or partial response to first-line platinum-based chemotherapy. • as monotherapy for the maintenance treatment of female adult patients with recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer who are in a complete or partial response to platinum-based chemotherapy.
- Zejula is indicated: as monotherapy for the maintenance treatment of adult patients with advanced epithelial (FIGO Stages III and IV) high-grade ovarian, fallopian tube or primary peritoneal cancer who are in response (complete or partial) following completion of first-line platinum-based chemotherapy. as monotherapy for the maintenance treatment of adult patients with platinum sensitive relapsed high grade serous epithelial ovarian, fallopian tube, or primary peritoneal cancer who are in response (complete or partial) to platinum based chemotherapy.
How the evidence outlook works ↗
Featured trials
The studies most instrumental to this drug's clinical progression, individually graded on design and result. The complete registry, including every study not featured here, is listed below.
| Trial | Phase | Endpoint | Key result | Signal | Source |
|---|---|---|---|---|---|
NCT02655016 NCT02655016 · Ovarian Cancer Patients were randomly assigned to niraparib or a matching placebo, with patients, doctors and outcome assessors all blinded. Progression-free survival, read by a blinded independent central review, was significantly longer with niraparib (hazard ratio 0.62, p<0.0001). The protocol reports a power calculation for this endpoint and 733 patients were enrolled against a planned 620. Registry: NCT02655016 | 3 | Progression Free Survival (Up to 34 months) 2019-05-17 | Progression Free Survival (Up to 34 months): Placebo 8.2 Months (95% CI 7.3 to 8.5) | Niraparib 13.8 Months (95% CI 11.5 to 14.9) | Reliable signal | link ↗ |
View 1 more trial
NCT01847274 NCT01847274 · Ovarian Cancer Niraparib was compared with a matching placebo in 553 randomly assigned patients, with participants, carers, investigators and assessors all blinded and progression read by blinded central review. All three primary progression-free survival comparisons were met: germline BRCA cohort (21.0 vs 5.5 months, hazard ratio 0.27), HRD-positive tumours without a germline BRCA mutation (hazard ratio 0.38) and the whole non-germline-BRCA cohort (hazard ratio 0.45), all p<0.0001. The protocol reports a power calculation, and enrolment (203 and 350 per cohort) exceeded the planned 180 and 310. Registry: NCT01847274 | 3 | Progression-Free Survival (PFS) in Cohort With Germline BReast CAncer Gene (BRCA) Mutation (gBRCA) (From date of randomization to the earliest date of disease progression or death from any cause, up to 7 years 7 months and 4 days); Progression-Free Survival (PFS) in Cohort With No Germline BCRA With Homologous Recombination Deficiency-positive (HRD+) Tumors (Non-gBRCAmut HRD+) (From date of randomization to the earliest date of disease progression or death from any cause, up to 7 years, 7 months and 4 days); Progression-Free Survival (PFS) in Cohort With No Germline BRCA Mutation (From date of randomization to the earliest date of disease progression or death from any cause, up to 7 years, 7 months and 4 days) 2016-04-22 | Completed. Key figures are not recorded here; the rationale explains the result. | Reliable signal | link ↗ |
All registered studies
Every ClinicalTrials.gov study of this drug's own program. Studies backing a featured trial above are marked Featured; the rest aren't individually graded. Filter by which indication a study was run for, then browse by phase. Studies where this drug served as another program's comparator, or is merely referenced, are listed separately below.
Phase 3 (21)
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
Phase 2/3 (2)
What this study did
What this study did
Phase 2 (100)
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
Phase 1/2 (23)
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
Phase 1 (46)
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
Phase 4 (5)
What this study did
What this study did
What this study did
What this study did
What this study did
Early phase / not applicable (1)
What this study did
Used as active comparator (1)
Other programs' studies in which this drug was the registered active-comparator arm: a marker of standard-of-care status, not evidence of this drug's own progression.
Phase 1/2 (1)
What this study did
Appears in other studies (4)
Studies that reference this drug without giving it an intervention arm of its own: other formulations' programs, background therapy, or registry-search bleed.
Phase 3 (1)
What this study did
Phase 2 (3)
What this study did
What this study did
What this study did
Competitive landscape
Other PARP1/2 drugs
1 other tracked programme targets this mechanism, none of them ahead of this one.
This drug's own stage for Ovarian Cancer: Approved. Competitors below are sorted furthest-along first.
| Drug | Stage | Modality | Mechanism | Evidence signal | Reported efficacygraded featured trials | |
|---|---|---|---|---|---|---|
| Niraparib: this drug | Approved | Small molecule | PARP1/2 | Reliable signal | NCT02655016: Progression Free Survival (Up to 34 months): Placebo 8.2 Months (95% CI 7.3 to 8.5) | Niraparib 13.8 Months (95% CI 11.5 to 14.9) | |
| Avutometinib / Defactinib (Avmapki Fakzynja Co-Pack) | Approved | Small molecule | MEK1/2 and RAF (CRAF, BRAF), FAK | not yet graded | No reviewed efficacy summary in this indication | |
| BAT1706 (Avzivi) | Approved | Monoclonal antibody | VEGF-A | not yet graded | No reviewed efficacy summary in this indication | |
| Bevacizumab | Approved | Monoclonal antibody | VEGF-A, Vascular Endothelial Growth Factor Inhibitor | not yet graded | No reviewed efficacy summary in this indication | |
| Gemcitabine | ApprovedUS marketing discontinued | Small molecule | ribonucleotide reductase / DNA polymerase (dCTP competition) | not yet graded | No reviewed efficacy summary in this indication | |
| Jobevne (bevacizumab-Nwgd) | Approved | Monoclonal antibody | VEGF-A | not yet graded | No reviewed efficacy summary in this indication | |
| Mirvetuximab Soravtansine (Elahere) | Approved | Antibody–drug conjugate | — | not yet graded | No reviewed efficacy summary in this indication | |
| Olaparib | Approved | Small molecule | PARP | not yet graded | No reviewed efficacy summary in this indication | |
| Pembrolizumab | Approved | Monoclonal antibody | PD-1 | Reliable signal | No reviewed efficacy summary in this indication | |
| Relacorilant (Lifyorli) | Approved | Small molecule | Glucocorticoid receptor | Partial signal | No reviewed efficacy summary in this indication | |
| Rucaparib | Approved | Small molecule | PARP (poly ADP-ribose polymerase) enzymes, PARP1/2 | Reliable signal | Featured results are non-efficacy only in this race | |
| Vegzelma (bevacizumab-Adcd) | Approved | Monoclonal antibody | VEGF-A | not yet graded | No reviewed efficacy summary in this indication | |
| Durvalumab | Phase 3 | Monoclonal antibody | PD-L1 | not yet graded | No reviewed efficacy summary in this indication | |
| GSK 5733584 | Phase 3 | — | — | not yet graded | No reviewed efficacy summary in this indication | |
| INCB123667 | Phase 3 | Small molecule | CDK2 | not yet graded | No reviewed efficacy summary in this indication | |
| Izalontamab Brengitecan | Phase 3 | Antibody–drug conjugate | EGFR + HER3 | not yet graded | No reviewed efficacy summary in this indication | |
| Olvimulogene Nanivacirepvec | Phase 3 | Oncolytic virus | No discrete molecular target | not yet graded | No reviewed efficacy summary in this indication | |
| Raludotatug Deruxtecan | Phase 3 | Antibody–drug conjugate | CDH6 (Cadherin-6) | not yet graded | No reviewed efficacy summary in this indication | |
| Rinatabart Sesutecan (Rina-S) | Phase 3 | Antibody–drug conjugate | Folate receptor alpha (FRα) | not yet graded | No reviewed efficacy summary in this indication | |
| Sacituzumab Tirumotecan | Phase 3 | Antibody–drug conjugate | TROP2 | not yet graded | No reviewed efficacy summary in this indication | |
| Sofetabart Mipitecan | Phase 3 | Antibody–drug conjugate | Folate receptor alpha (FRα) | not yet graded | No reviewed efficacy summary in this indication | |
| Torvutatug Samrotecan | Phase 3 | Antibody–drug conjugate | Folate receptor alpha (FRα) | not yet graded | No reviewed efficacy summary in this indication | |
| Trastuzumab Brengitecan | Phase 3 | Antibody–drug conjugate | HER2 | not yet graded | No reviewed efficacy summary in this indication | |
| Trastuzumab Rezetecan | Phase 3 | Antibody–drug conjugate | HER2 | not yet graded | No reviewed efficacy summary in this indication | |
| Birinapant | Phase 2 | — | IAP (inhibitor of apoptosis) proteins | not yet graded | No reviewed efficacy summary in this indication | |
| Ixotatug Vedotin | Phase 2 | Antibody–drug conjugate | Claudin 6 (CLDN6) | not yet graded | No reviewed efficacy summary in this indication | |
| Stenoparib | Phase 2 | Small molecule | PARP1/2, Tankyrase 1/2 | not yet graded | No reviewed efficacy summary in this indication | |
| COM701 | Phase 1/2 | Monoclonal antibody | PVRIG (CD112R) | not yet graded | No reviewed efficacy summary in this indication | |
| REGN5668 | Phase 1/2 | Multispecific antibody | MUC16 x CD28 | not yet graded | No reviewed efficacy summary in this indication | |
| Rezatapopt | Phase 1/2 | Small molecule | p53 reactivator | not yet graded | No reviewed efficacy summary in this indication | |
| TUB-040 | Phase 1/2 | Antibody–drug conjugate | NaPi2b (sodium-dependent phosphate transporter, SLC34A2) | not yet graded | No reviewed efficacy summary in this indication | |
| Ubamatamab | Phase 1/2 | Monoclonal antibody | MUC16 x CD3 | not yet graded | No reviewed efficacy summary in this indication | |
| 27T51 | Phase 1 | Cell therapy | MUC16 | not yet graded | No reviewed efficacy summary in this indication | |
| ABBV-901 | Phase 1 | Undisclosed | Folate receptor alpha (FRα) | not yet graded | No reviewed efficacy summary in this indication | |
| APG-2449 | Phase 1 | Small molecule | FAK / ALK / ROS1 | not yet graded | No reviewed efficacy summary in this indication | |
| CRX100 | Phase 1 | Cell therapy | Cell-based oncolytic virus immunotherapy | not yet graded | No reviewed efficacy summary in this indication | |
| IDE-161 | Phase 1 | Small molecule | PARG | not yet graded | No reviewed efficacy summary in this indication | |
| XmAb541 | Phase 1 | Multispecific antibody | Claudin 6 (CLDN6) x CD3 | not yet graded | No reviewed efficacy summary in this indication | |
| Luveltamab Tazevibulin | Discontinued | Antibody–drug conjugate | Folate receptor alpha (FRα) | not yet graded | No reviewed efficacy summary in this indication |
Compare side by side
Upcoming events
(44 total)
Estimated primary-completion dates from ClinicalTrials.gov. These are registry estimates, never confirmed readout dates; they can move as trials progress.
Follow Niraparib to get an email as a readout nears, when a date moves, or when a study changes status. Needs a free account.
Add these readouts to your calendar: Apple or Outlook · Google Calendar · .ics link. The calendar updates when a registry date moves.
2026 (9)
November 2026 (2)
December 2026 (7)
What to watch
What to watch
What to watch
What to watch
What to watch
What to watch
What to watch
2027 (19)
January 2027 (1)
What to watch
February 2027 (2)
March 2027 (3)
What to watch
What to watch
What to watch
April 2027 (1)
What to watch
May 2027 (1)
What to watch
June 2027 (3)
What to watch
What to watch
What to watch
August 2027 (1)
What to watch
September 2027 (2)
November 2027 (1)
What to watch
December 2027 (4)
What to watch
What to watch
What to watch
What to watch
2028 (8)
January 2028 (1)
What to watch
June 2028 (2)
What to watch
What to watch
July 2028 (1)
What to watch
August 2028 (1)
What to watch
December 2028 (3)
What to watch
What to watch
What to watch
2029 (5)
April 2029 (1)
What to watch
June 2029 (1)
What to watch
July 2029 (1)
What to watch
August 2029 (1)
What to watch
December 2029 (1)
What to watch
2030 (1)
December 2030 (1)
What to watch
Regulatory and conference events
(1)
Filings, regulator decisions, scientific presentations, topline results and licensing deals, each from a dated source. When a source gives only the month, the month is shown.
Recent